Get the Stockscreener App
6.55
0.30%
-0.02
After Hours:
6.46
-0.09
-1.37%
Larimar Therapeutics Inc stock is traded at $6.55, with a volume of 835.66K.
It is down -0.30% in the last 24 hours and down -17.19% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$6.57
Open:
$6.49
24h Volume:
835.66K
Relative Volume:
1.48
Market Cap:
$410.91M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-7.1196
EPS:
-0.92
Net Cash Flow:
$-33.46M
1W Performance:
+1.08%
1M Performance:
-17.19%
6M Performance:
-13.70%
1Y Performance:
+65.82%
1-Day Range:
$6.43
$6.60
1-Week Range:
$6.15
$6.72
52-Week Range:
$2.18
$13.68
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
Larimar Therapeutics Inc Stock (LRMR) Latest News
Driehaus Capital Management LLC Has $9.53 Million Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Average Rating of "Buy" by Brokerages - MarketBeat
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Average Rating of “Buy” by Brokerages - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Stock Position Decreased by Blue Owl Capital Holdings LP - MarketBeat
Larimar Therapeutics Inc [LRMR] Records 50-Day SMA of $7.92 - Knox Daily
Aprea Therapeutics to Present at Lytham Partners Fall Investor Conference - MyChesCo
Taking on analysts’ expectations and winning: Larimar Therapeutics Inc (LRMR) - SETE News
The LRMR Tug-of-War: 2023’s Market Gains and Losses Analyzed - The InvestChronicle
(LRMR) Trading Signals - Stock Traders Daily
Larimar Therapeutics Inc’s results are impressive - US Post News
Larimar Therapeutics Inc (LRMR) Becoming More Attractive for Investors - Knox Daily
Ratio Examination: Larimar Therapeutics Inc (LRMR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MSN
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
Director Hamilton Thomas Edward acquired 57,208 shares of Larimar Therapeutics Inc [LRMR] - Knox Daily
Larimar Therapeutics Announces Three Poster Presentations - GlobeNewswire
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research - StockTitan
Thoroughbred Financial Services LLC Takes Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Check Out Larimar Therapeutics Inc (LRMR)’s Trade Data Rather Than the Analysts’ Views - SETE News
Larimar Therapeutics Inc [LRMR] Investment Appeal on the Rise - Knox Daily
A stock that deserves closer examination: Larimar Therapeutics Inc (LRMR) - US Post News
Closing Figures: Larimar Therapeutics Inc (LRMR)’s Negative Finish at 7.20, Down -0.55 - The Dwinnex
(LRMR) Technical Data - Stock Traders Daily
Ballentine Partners LLC Invests $137,000 in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
A Guide To The Risks Of Investing In Larimar Therapeutics Inc (LRMR) - Knox Daily
Larimar Therapeutics (NASDAQ:LRMR) Shares Up 6.1% - MarketBeat
Larimar Therapeutics Inc (LRMR) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) Price Target at $21.33 - Defense World
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Down 4.7% - MarketBeat
Larimar Therapeutics Inc (LRMR) is looking forward to a strong quarter - SETE News
Larimar Therapeutics (NASDAQ:LRMR) Sees Unusually-High Trading Volume - MarketBeat
Larimar Therapeutics Inc [LRMR] Records 200-Day SMA of $7.29 - Knox Daily
Metric Analysis: Larimar Therapeutics Inc (LRMR)’s Key Ratios in the Limelight - The Dwinnex
Larimar Therapeutics (NASDAQ:LRMR) Lifted to Strong-Buy at Baird R W - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated by Analysts at Robert W. Baird - Defense World
Larimar Therapeutics (NASDAQ:LRMR) Receives New Coverage from Analysts at Robert W. Baird - MarketBeat
Baird initiates coverage on Larimar Therapeutics shares with Outperform rating - Investing.com Canada
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Baird initiates coverage on Larimar Therapeutics shares with Outperform rating - Investing.com UK
Baird Initiates Coverage of Larimar Therapeutics (LRMR) with Outperform Recommendation - MSN
Keeping an Eye on Larimar Therapeutics Inc (LRMR) After Insider Trading Activity - Knox Daily
(LRMR) Investment Analysis - Stock Traders Daily
Larimar Therapeutics Engages with Investors at Key Conferences - MSN
Larimar Therapeutics Engages with Investors at Key Conferences - MyChesCo
Larimar Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Larimar Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance UK
Larimar Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Larimar Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
Understanding the Risks of Investing in Larimar Therapeutics Inc (LRMR) - Knox Daily
There is no way Larimar Therapeutics Inc (LRMR) can keep these numbers up - SETE News
Larimar Therapeutics Inc (LRMR) rating initates by Leerink Partners - Knox Daily
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):